1838 related articles for article (PubMed ID: 25923331)
21. Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status of cloned embryos.
Saini M; Selokar NL; Agrawal H; Singla SK; Chauhan MS; Manik RS; Palta P
Reprod Fertil Dev; 2016 Apr; 28(6):824-37. PubMed ID: 25409339
[TBL] [Abstract][Full Text] [Related]
22. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu WG; Lakshmanan RR; Beal MD; Otterson GA
Cancer Res; 2001 Feb; 61(4):1327-33. PubMed ID: 11245429
[TBL] [Abstract][Full Text] [Related]
23. Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.
Sanaei M; Kavoosi F; Pourahmadi M
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2089-2098. PubMed ID: 34319031
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.
Ecke I; Petry F; Rosenberger A; Tauber S; Mönkemeyer S; Hess I; Dullin C; Kimmina S; Pirngruber J; Johnsen SA; Uhmann A; Nitzki F; Wojnowski L; Schulz-Schaeffer W; Witt O; Hahn H
Cancer Res; 2009 Feb; 69(3):887-95. PubMed ID: 19155313
[TBL] [Abstract][Full Text] [Related]
25. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Feingold PL; Surman DR; Brown K; Xu Y; McDuffie LA; Shukla V; Reardon ES; Crooks DR; Trepel JB; Lee S; Lee MJ; Gao S; Xi S; McLoughlin KC; Diggs LP; Beer DG; Nancarrow DJ; Neckers LM; Davis JL; Hoang CD; Hernandez JM; Schrump DS; Ripley RT
Mol Cancer Ther; 2018 Sep; 17(9):2013-2023. PubMed ID: 29934340
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of KLF4 by methylseleninic acid in human esophageal squamous cell carcinoma cells: Modification of histone H3 acetylation through HAT/HDAC interplay.
Hu C; Liu M; Zhang W; Xu Q; Ma K; Chen L; Wang Z; He S; Zhu H; Xu N
Mol Carcinog; 2015 Oct; 54(10):1051-9. PubMed ID: 24789055
[TBL] [Abstract][Full Text] [Related]
27. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
28. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
30. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
31. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
33. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
34. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
[TBL] [Abstract][Full Text] [Related]
35. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
36. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
37. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
39. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
40. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
